Utilizing Clinical Pathways in Ovarian Cancer

Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the use of PARP inhibitors within the treatment landscape for ovarian cancer.

Dr Haumschild explores considerations for safe and appropriate dosing for patients receiving PARP inhibitor therapy.

The significance of multidisciplinary teams in ovarian cancer treatment is highlighted.

Dr Haumschild discusses the substantial impact of clinical pathways in the treatment of ovarian cancer.

Dr Haumschild navigates financial considerations associated with treatment of ovarian cancer.

Quality of life and safety profiles are discussed by Ryan Haumschild, PharmD, MS, MBA.

A medical expert navigates clinical pathway considerations in the treatment of ovarian cancer.

In his closing thoughts, Dr Haumschild discusses unmet needs in the treatment landscape for ovarian cancer.